| Identification | Back Directory | [Name]
Bcl-2/Bcl-xl inhibitor 1 | [CAS]
2180923-05-9 | [Synonyms]
APG-2575
Lisaftoclax
APG-2575 (lisaftoclax)
Bcl-2/Bcl-xl inhibitor 1 | [Molecular Formula]
C45H48ClN7O8S | [MDL Number]
MFCD34469554 | [MOL File]
2180923-05-9.mol | [Molecular Weight]
882.42 |
| Chemical Properties | Back Directory | [density ]
1.48±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
4.07±0.10(Predicted) | [color ]
Light yellow to yellow | [InChIKey]
FNBXDBIYRAPDPI-BHVANESWSA-N | [SMILES]
C(NS(C1=CC=C(NC[C@H]2COCCO2)C([N+]([O-])=O)=C1)(=O)=O)(=O)C1=CC=C(N2CCN(CC3CCC4(CCC4)CC=3C3=CC=C(Cl)C=C3)CC2)C=C1OC1=CN=C2NC=CC2=C1 |
| Hazard Information | Back Directory | [Uses]
Lisaftoclax (compound 6) is a dual Bcl-2 and Bcl-xl inhibitor with anti-tumor activity, extracted from patent WO2018027097A1. Lisaftoclax exhibits IC50 values of 2 nM and 5.9 nM for Bcl-2 and Bcl-xl, respectively[1]. | [IC 50]
Bcl-2: 2 nM (IC50); Bcl-xL: 5.9 nM (IC50) | [References]
[1] WANG, Chia, et al. N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS. Patent. WO2018027097A1. |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|